Nazish Malik

Nazish Malik

Auto-generated profile, based on publicly available information

Nazish Malik

Division of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Shi-Ming TuShi-Ming Tu
Shi-Ming Tu
ATAnup K. Trikannad
Anup K. Trikannad
SVSruthi Vellanki Sruthi Vellanki
Sruthi Vellanki Sruthi Vellanki
MHMunawwar Hussain
Munawwar Hussain
NMNazish Malik
Nazish Malik
OAOmar T. Atiq
Omar T. Atiq
Although immunotherapy has revolutionized cancer care, there is still an urgent need to enhance its efficacy and ensure its safety. A correct cancer theory and proper scientific method empower pertinent cancer research and enable effective and efficient drug versus therapy development for patient care. In this perspective, we revisit the concept of immune privilege in a cancer cell versus normal cell, as well as in a cancer stem cell versus normal stem cell. We re-examine whether effective immunotherapies are efficacious due to their anti-cancer and/or immune modulatory mechanisms. We reassess why checkpoint inhibitors (CPIs) are not equal. We reconsider whether one can attribute the utility of immunotherapy to specific cancer subtypes and its futility to certain tumor/immune compartments, components, and microenvironments. We propose ways and means to advance immunotherapy beyond CPIs by combining anti-PD1/L1 with various other treatment modalities according to an appropriate scientific theory, e.g., stem cell origin of cancer, and based on available clinical evidence, e.g., randomized clinical trials. We predict that a stem cell theory of cancer will facilitate the design of better and safer immunotherapy with improved selection of its use for the right patient with the right cancer type at the right time to optimize clinical benefits and minimize potential toxic effects and complications.